E. Kneepkens
About
E. Kneepkens is a scholar working on Rheumatology, Hematology and Immunology.
According to data from OpenAlex, E. Kneepkens has authored 26 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Rheumatology, 10 papers in Hematology and 10 papers in Immunology. Recurrent topics in E. Kneepkens's work include Rheumatoid Arthritis Research and Therapies (20 papers), Spondyloarthritis Studies and Treatments (10 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). E. Kneepkens is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Spondyloarthritis Studies and Treatments (10 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). E. Kneepkens collaborates with scholars based in Netherlands, United States and Spain. E. Kneepkens's co-authors include Michael T. Nurmohamed, Gertjan Wolbink, Theo Rispens, C. Krieckaert, Desirée van der Kleij, Karien Bloem, Erik H Vogelzang, Annick de Vries, Irene E. van der Horst‐Bruinsma and Arno W. R. van Kuijk and has published in prestigious journals such as PLoS ONE, Annals of the Rheumatic Diseases and Frontiers in Pharmacology.
In The Last Decade
E. Kneepkens
26 papers receiving 428 citations
Peers
E. Kneepkens
H.L.M. Brus Netherlands
Stefan Kleinert Germany
Benjamin D Clarke United Kingdom
P Müller Netherlands
Cynthia Madden United States
J. L. Hülsemann Germany
P. Santos-Moreno Colombia
Marie‐Pierre Desrosiers United States
KY Fong Singapore
E Bruschi Italy
Citations per year, relative to E. Kneepkens E. Kneepkens (= 1×)
peers
H.L.M. Brus
Countries citing papers authored by E. Kneepkens
Since
Specialization
Citations
This map shows the geographic impact of E. Kneepkens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Kneepkens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Kneepkens more than expected).
Fields of papers citing papers by E. Kneepkens
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by E. Kneepkens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Kneepkens. The network helps show where E. Kneepkens may publish in the future.
Co-authorship network of co-authors of E. Kneepkens
This figure shows the co-authorship network connecting the top 25 collaborators of E. Kneepkens. A scholar is included among the top collaborators of E. Kneepkens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Kneepkens. E. Kneepkens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Uitvlugt, Elien B., Marjo J. A. Janssen, C. E. H. Siegert, et al.. (2021). Medication-Related Hospital Readmissions Within 30 Days of Discharge: Prevalence, Preventability, Type of Medication Errors and Risk Factors. Frontiers in Pharmacology. 12. 567424–567424.
2.
Kneepkens, E., Elien B. Uitvlugt, Sofieke C. Wijers, et al.. (2020). Preventability of unplanned readmissions within 30 days of discharge. A cross-sectional, single-center study. PLoS ONE. 15(4). e0229940–e0229940.
3.
Kneepkens, E., C. Krieckaert, Michael T. Nurmohamed, et al.. (2020). OP0209 INTERVAL PROLONGATION IN ETANERCEPT-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS: AN OPEN-LABEL, RANDOMISED CONTROLLED TRIAL. Annals of the Rheumatic Diseases. 79. 130–130.
4.
Hernández‐Breijo, Borja, Chamaida Plasencia‐Rodríguez, Victoria Navarro‐Compán, et al.. (2019). Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Research & Therapy. 21(1). 66–66.
5.
Hernández‐Breijo, Borja, Victoria Navarro‐Compán, Ana Martínez‐Feito, et al.. (2018). FRI0186 Concomitant csdmards influence clinical response to tnf inhibitors only in overweight patients with axial spondyloarthritis. Annals of the Rheumatic Diseases. 77. 634–634.
6.
Bloem, Karien, Ronald S. Boshuizen, E. Kneepkens, et al.. (2018). Capillary Blood Microsampling to Determine Serum Biopharmaceutical Concentration: Mitra ® Microsampler vs Dried Blood Spot. Bioanalysis. 10(11). 815–823.
7.
Klooster, Peter M. ten, Harald E. Vonkeman, E. Kneepkens, et al.. (2017). Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients’ Burden of Disease. Arthritis Care & Research. 70(4). 516–524.
8.
Heslinga, Maaike, et al.. (2017). The Effects of 5-year Etanercept Therapy on Cardiovascular Risk Factors in Patients with Psoriatic Arthritis. The Journal of Rheumatology. 44(9). 1362–1368.
9.
Kneepkens, E., et al.. (2017). Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.. PubMed. 35(3). 431–437.
10.
Moens, Sophie J. Bernelot, Fleur M. van der Valk, Aart C. Strang, et al.. (2016). Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. Arthritis Research & Therapy. 18(1). 115–115.
11.
Weely, Salima van, E. Kneepkens, Michael T. Nurmohamed, Joost Dekker, & Irene E. van der Horst‐Bruinsma. (2016). Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three‐Year Followup and Predictors. Arthritis Care & Research. 68(10). 1522–1529.
12.
Plasencia, Chamaida, E. Kneepkens, Gertjan Wolbink, et al.. (2015). Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity. The Journal of Rheumatology. 42(9). 1638–1646.
13.
Kneepkens, E., et al.. (2015). SAT0156 The Effect of Methotrexate in Treatment with Adalimumab And Etanercept in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 74. 708–709.
14.
Kneepkens, E., Erik H Vogelzang, Irene van der Horst‐Bruinsma, et al.. (2015). THU0208 Efficacy of Switching Tumor Necrosis Factor α Inhibitor to a Second Tumor Necrosis Factor α Inhibitor and the Influence of Drug Levels and Anti-Drug Antibodies in Patients with Ankylosing Spondylitis and Psoriatic Arthritis. Annals of the Rheumatic Diseases. 74. 271–271.
15.
Kneepkens, E., et al.. (2015). AB1098 Patient Reported Reasons for Refraining from Participation in Dose Reduction Studies with Biologics. Annals of the Rheumatic Diseases. 74. 1268–1268.
16.
Vogelzang, Erik H, E. Kneepkens, Michael T. Nurmohamed, et al.. (2014). SAT0391 A Diminished Clinical Response at 28 and 52 Weeks of Adalimumab Treatment in Patients with Psoriatic Arthritis is Associated with Anti-Drug Antibodies. Annals of the Rheumatic Diseases. 73. 735–736.
17.
Kneepkens, E., C. Krieckaert, Desirée van der Kleij, et al.. (2014). Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Annals of the Rheumatic Diseases. 74(10). 1825–1829.
18.
Vogelzang, Erik H, E. Kneepkens, Michael T. Nurmohamed, et al.. (2014). Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Annals of the Rheumatic Diseases. 73(12). 2178–2182.
19.
Kneepkens, E., James Cheng‐Chung Wei, Michael T. Nurmohamed, et al.. (2013). Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Annals of the Rheumatic Diseases. 74(2). 396–401.
20.
Kneepkens, E., James Cheng‐Chung Wei, Michael T. Nurmohamed, et al.. (2013). FRI0426 Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up.. Annals of the Rheumatic Diseases. 72. A518–A519.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by H.L.M. Brus Breakdown of academic impact, for papers by Stefan Kleinert Breakdown of academic impact, for papers by Benjamin D Clarke Breakdown of academic impact, for papers by P Müller Breakdown of academic impact, for papers by Cynthia Madden Breakdown of academic impact, for papers by J. L. Hülsemann Breakdown of academic impact, for papers by P. Santos-Moreno Breakdown of academic impact, for papers by Marie‐Pierre Desrosiers Breakdown of academic impact, for papers by KY Fong Breakdown of academic impact, for papers by E Bruschi